Bicycle Therapeutics PLC
NASDAQ:BCYC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
Bicycle Therapeutics PLC (BCYC) under the Base Case is 0.6 USD per share.
Compared with the current market price of 3.69 USD, the stock appears
Overvalued by 84% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Bicycle Therapeutics Does
Bicycle Therapeutics is a biotechnology company that designs and develops a new class of medicines called bicycle molecules, which are short synthetic peptides shaped to bind tightly to disease targets. Its main focus is cancer, and it also works on other serious diseases where precise targeting could matter. The company is still in the drug-development stage, so its business is centered on discovering, testing, and advancing candidates rather than selling a large portfolio of approved medicines.
- Headquarters
- United Kingdom UK
- Employees
- 288
- IPO date
- May 23, 2019
Revenue & Expenses Breakdown
Bicycle Therapeutics PLC
Earnings Waterfall
Bicycle Therapeutics PLC
What is the Intrinsic Value of one BCYC stock?
The intrinsic value for Bicycle Therapeutics PLC (BCYC) under the Base Case is 0.6 USD.
Is BCYC stock undervalued or overvalued?
Compared with the current market price of 3.69 USD, the stock appears Overvalued by 84% .
